Climb Bio (CLYM) Consolidated Net Income (2020 - 2026)

Climb Bio filings provide 7 years of Consolidated Net Income readings, the most recent being -$13.7 million for Q1 2026.

  • Quarterly Consolidated Net Income rose 33.93% to -$13.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$52.5 million through Mar 2026, up 43.49% year-over-year, with the annual reading at -$59.6 million for FY2025, 19.39% up from the prior year.
  • Consolidated Net Income hit -$13.7 million in Q1 2026 for Climb Bio, up from -$17.5 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at -$1.7 million in Q1 2024 and bottomed at -$54.9 million in Q2 2024.
  • Average Consolidated Net Income over 5 years is -$13.3 million, with a median of -$8.9 million recorded in 2024.
  • The largest annual shift saw Consolidated Net Income skyrocketed 92.62% in 2024 before it crashed 1145.85% in 2025.
  • Climb Bio's Consolidated Net Income stood at -$8.8 million in 2022, then skyrocketed by 57.1% to -$3.8 million in 2023, then tumbled by 122.37% to -$8.4 million in 2024, then crashed by 108.22% to -$17.5 million in 2025, then rose by 21.6% to -$13.7 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Consolidated Net Income are -$13.7 million (Q1 2026), -$17.5 million (Q4 2025), and -$12.9 million (Q3 2025).